Pharsight

1. Cetrotide patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7605121	EMD SERONO INC	Oligopeptide lyophilisate, their preparation and use	Feb, 2014 (10 years ago)
US6863891	EMD SERONO INC	Oligopeptide lyophilisate, their preparation and use	Feb, 2014 (10 years ago)
US6319192	EMD SERONO INC	Method for the treatment of fertility disorders	Apr, 2019 (4 years ago)

Drugs and Companies using CETRORELIX ACETATE ingredient

Market Authorisation Date: 11 August, 2000

Treatment: Prevention of premature lh surges in women undergoing controlled ovarian stimulation

Dosage: POWDER;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 0.25MG BASE/VIAL	POWDER;SUBCUTANEOUS	Prescription
EQ 3MG BASE/VIAL	POWDER;SUBCUTANEOUS	Discontinued

CETROTIDE family patents

2. Glucophage Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6660300	EMD SERONO INC	Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method	Mar, 2018 (6 years ago)
US6475521	EMD SERONO INC	Biphasic controlled release delivery system for high solubility pharmaceuticals and method	Mar, 2018 (6 years ago)

Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 13 October, 2000

Treatment: Method of treating patient with type 2 diabetes by once daily administration

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
750MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued

GLUCOPHAGE XR family patents

3. Mavenclad patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP14001970A	2018-10-16	Generics (UK) Ltd	Granted and Under Opposition

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10849919	February, 2023	Terminated-Settled	Ares Trading SA	Hopewell Pharma Ventures, Inc. et al.
US7713947	January, 2023	PO preliminary response filed	Merck Serono SA	Hopewell Pharma Ventures, Inc. et al.
US8377903	January, 2023	PO preliminary response filed	Merck Serono SA	Hopewell Pharma Ventures, Inc. et al.
US7713947	October, 2022	Institution Denied	Merck Serono SA	TWi Pharmaceuticals, Inc.
US8377903	October, 2022	Institution Denied	Merck Serono SA	TWi Pharmaceuticals, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785415	EMD SERONO INC	Oral formulations of cladribine	Apr, 2024 (9 days ago)
US7888328	EMD SERONO INC	Oral formulations of cladribine	Apr, 2024 (9 days ago)
US8377903	EMD SERONO INC	Cladribine regimen for treating multiple sclerosis	May, 2026 (2 years from now)
US7713947	EMD SERONO INC	Cladribine regimen for treating multiple sclerosis	Oct, 2026 (2 years from now)
US10849919	EMD SERONO INC	Cladribine regimen for treating progressive forms of multiple sclerosis	Nov, 2038 (14 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Mar 29, 2022

Drugs and Companies using CLADRIBINE ingredient

Market Authorisation Date: 29 March, 2019

Treatment: Treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a s...

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg	07 Apr, 2022	1		16 Oct, 2026

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription

MAVENCLAD family patents

4. Tepmetko patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8921357	EMD SERONO INC	Pyridazinone derivatives	May, 2028 (4 years from now)
US8329692	EMD SERONO INC	Pyrimidinyl pyridazinone derivatives	Oct, 2029 (5 years from now)
US8580781	EMD SERONO INC	Pyridazinone derivatives	Mar, 2030 (5 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9284300	EMD SERONO INC	Pyridazinone derivatives	Apr, 2028 (4 years from now)
US8658643	EMD SERONO INC	Pyrimidinyl pyridazinone derivatives	Jul, 2028 (4 years from now)
US9403799	EMD SERONO INC	Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase	Jul, 2028 (4 years from now)
US9062029	EMD SERONO INC	Pyrimidinyl pyridazinone derivatives	Jul, 2028 (4 years from now)
US8927540	EMD SERONO INC	Pyridazinone derivatives	Jul, 2028 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE)	Feb 03, 2026
Orphan Drug Exclusivity(ODE-325)	Feb 03, 2028

Drugs and Companies using TEPOTINIB HYDROCHLORIDE ingredient

NCE-1 date: 03 February, 2025

Market Authorisation Date: 03 February, 2021

Treatment: Treating a solid tumor, including lung cancer, with a met alteration(s), or stabilizing or improving symptoms associated with having a solid tumor, including lung cancer, with a met alteration(s), by ...